Bilimsel Makale Arama | NeuralCipher AI

Kaynak kaydı

LRRK2 G2019S as a shared mutation in two distinct double-mutant Parkinson's disease cases: First cases from Tunisia.

Mousli AA, Zouari R, Agrebaoui A, Zakaria S, Marzouki B, Nahdi H, Nabli F, Rachdi A, Ben Mohamed D, Ben Sassi S.

Parkinsonism Relat Disord · 2026-06-01

DOI: 10.1016/j.parkreldis.2026.108375PMID: 42235482

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Preformed fibrils of α-synuclein rapidly activate LRRK2 on early endosomes, driving Rab5 phosphorylation and disrupting endolysosomal and synaptic function.

Zuo X, Chen Z, Chen XQ, Guan D, Shaw PX, Johnstone A, Becker A, Das U, Mobley WC.

NPJ Parkinsons Dis · 2026-05-12

DOI: 10.1038/s41531-026-01382-zPMID: 42120407

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

A novel insight into the risk of depression and anxiety onset in Parkinson's disease: the implications of GBA1 and LRRK2.

Yang D, Wang J, Huang H, Lin S, Liu Z, Zhang S, Xu J, Zhang B, Cai H, Lin H, Huang S, Chen G.

Parkinsonism Relat Disord · 2026-05-07

DOI: 10.1016/j.parkreldis.2026.108341PMID: 42114177

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Mechanistic multiscale modeling identifies putative natural tri-target candidates of MAO-B, LRRK2 and A₂A for Parkinson's disease.

Khibech O, Kadda S, Abadi S, Benabbou A, Bouhrim M, Jodeh S, Jodeh D, Hammouti B, Challioui A.

Sci Rep · 2026-05-05

DOI: 10.1038/s41598-026-50523-0PMID: 42086777

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease".

Yu EC, Zhou H, Yan X, Logan KM, Li D, Gulati A, Poremba KE, Ardolino MJ, Su J, Xiao D, Palte RL, McMinn SE, Nogle LM, Adpressa DA, Burgess SA, Xiong T, Otte KM, Chobanian HR, Bass A, Lee S, Pearson K, Messina E, Parisi M, Barnum J, Sobol Z, Ciaccio PJ, DiMauro EF, Fell MJ, Fuller PH.

J Med Chem · 2026-04-27

DOI: 10.1021/acs.jmedchem.6c01130PMID: 42045162

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Disruption of the LRRK2 substrate RAB12 facilitates neurotransmission and causes hyperactivity in mice.

Li X, Chen Y, Wang H, Zhang X, Guiberson NGL, Li X, Burré J, Peng J, Zhang H, Yue Z.

NPJ Parkinsons Dis · 2026-04-24

DOI: 10.1038/s41531-026-01353-4PMID: 42031745

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

<i>LRRK2</i> mutations: at the crossroads of dopamine, iron, and calcium imbalance in Parkinson's disease.

Skarżyńska W, Moskal A, Kuźnicki J.

Acta Neurobiol Exp (Wars) · 2026-04-24

DOI: 10.55782/kre63y59PMID: 42370616

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease.

Toh TS, Lit LC, Lim SY, Hor JW, Lew CY, Khairul Anuar AN, Tay YW, Black K, Lim JL, Zulkefli J, Lim KS, Ding HX, Padmanabhan S, Ahmad-Annuar A, Tan EK, Alessi DR, Sammler E, Tan AH.

Mov Disord · 2026-04-20

DOI: 10.1002/mds.70314PMID: 42003785

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Clinical Progression in Alpha-Synuclein Positive LRRK2-PD and Sporadic Parkinson's Disease: A Longitudinal Analysis.

Morse LA, Choi SH, Gochanour C, Lafontant DE, Chahine LM, Merchant KM, Wendelberger B, Simuni T, Parkinson's Progression Markers Initiative.

Mov Disord Clin Pract · 2026-04-19

DOI: 10.1002/mdc3.70640PMID: 42003081

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Synergistic Effects of Multi-Kinase Inhibition on <i>LRRK2</i>-G2019S and Alpha-Synuclein Pathologies in Models of Parkinson's Disease.

Liu X, Baxley S, Hebron ML, Moussa C.

Biomedicines · 2026-04-18

DOI: 10.3390/biomedicines14040927PMID: 42072468

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

LRRK2 I1371V Mutation Drives Astrocytic Glucose Metabolism Failure and Induces Integrated ER-Mitochondria-Lysosome Dysfunction in Parkinson's Disease.

Banerjee R, Santhoshkumar R, Holla V, Kamble N, Yadav R, Pal PK, Datta I.

Int J Mol Sci · 2026-04-12

DOI: 10.3390/ijms27083463PMID: 42074107

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Lack of Cerebrospinal Fluid α-Synuclein Seeding in VPS35 D620N- and LRRK2 Y1699C-Linked Parkinson's Disease.

Santinelli L, Pratuseviciute N, Lange LM, Kleinz T, Brüggemann N, Streubel-Gallasch L, Möller M, Zimprich A, Brücke C, Good JM, Griebner N, Padmanabhan S, Seibler P, Bauer P, Vandenberghe W, Sammler E, Blauwendraat C, Klein C, Borsche M.

Mov Disord · 2026-03-30

DOI: 10.1002/mds.70291PMID: 41912440

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.

785 makale bulundu

LRRK2 G2019S as a shared mutation in two distinct double-mutant Parkinson's disease cases: First cases from Tunisia.

Preformed fibrils of α-synuclein rapidly activate LRRK2 on early endosomes, driving Rab5 phosphorylation and disrupting endolysosomal and synaptic function.

A novel insight into the risk of depression and anxiety onset in Parkinson's disease: the implications of GBA1 and LRRK2.

Mechanistic multiscale modeling identifies putative natural tri-target candidates of MAO-B, LRRK2 and A₂A for Parkinson's disease.

Correction to "Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease".

Disruption of the LRRK2 substrate RAB12 facilitates neurotransmission and causes hyperactivity in mice.

<i>LRRK2</i> mutations: at the crossroads of dopamine, iron, and calcium imbalance in Parkinson's disease.

Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease.

Clinical Progression in Alpha-Synuclein Positive LRRK2-PD and Sporadic Parkinson's Disease: A Longitudinal Analysis.

Synergistic Effects of Multi-Kinase Inhibition on <i>LRRK2</i>-G2019S and Alpha-Synuclein Pathologies in Models of Parkinson's Disease.

LRRK2 I1371V Mutation Drives Astrocytic Glucose Metabolism Failure and Induces Integrated ER-Mitochondria-Lysosome Dysfunction in Parkinson's Disease.

Lack of Cerebrospinal Fluid α-Synuclein Seeding in VPS35 D620N- and LRRK2 Y1699C-Linked Parkinson's Disease.

Filtreler